Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.

Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET, Klibanski A.

J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25. doi: 10.1210/jc.2007-2633. Epub 2008 Jul 15.

2.

Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas.

Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y, Rice KA, Tessa Hedley-Whyte E, Swearingen B, Klibanski A.

Am J Pathol. 2011 Oct;179(4):2120-30. doi: 10.1016/j.ajpath.2011.07.002. Epub 2011 Aug 24.

3.

Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas.

Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, Petersenn S.

Horm Metab Res. 2014 Aug;46(9):644-50. doi: 10.1055/s-0034-1383566. Epub 2014 Aug 15.

PMID:
25126861
4.

Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.

Ruebel KH, Jin L, Zhang S, Scheithauer BW, Lloyd RV.

Endocr Pathol. 2001 Fall;12(3):281-9.

PMID:
11740049
5.

Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors.

Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A.

J Clin Endocrinol Metab. 2005 Apr;90(4):2179-86. Epub 2005 Jan 11.

PMID:
15644399
6.

Expression of neuro D1 in human normal pituitaries and pituitary adenomas.

Oyama K, Sanno N, Teramoto A, Osamura RY.

Mod Pathol. 2001 Sep;14(9):892-9.

7.

Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas.

Mezzomo LC, Gonzales PH, Pesce FG, Kretzmann Filho N, Ferreira NP, Oliveira MC, Kohek MB.

Pituitary. 2012 Sep;15(3):420-7. doi: 10.1007/s11102-011-0340-1.

PMID:
21850407
8.

Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.

Revill K, Dudley KJ, Clayton RN, McNicol AM, Farrell WE.

Endocr Relat Cancer. 2009 Jun;16(2):537-48. doi: 10.1677/ERC-09-0008. Epub 2009 Feb 13.

9.

Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.

Morris DG, Kola B, Borboli N, Kaltsas GA, Gueorguiev M, McNicol AM, Ferrier R, Jones TH, Baldeweg S, Powell M, Czirják S, Hanzély Z, Johansson JO, Korbonits M, Grossman AB.

J Clin Endocrinol Metab. 2003 Dec;88(12):6080-7.

PMID:
14671214
10.

Epigenetic silencing of genes and microRNAs within the imprinted Dlk1-Dio3 region at human chromosome 14.32 in giant cell tumor of bone.

Lehner B, Kunz P, Saehr H, Fellenberg J.

BMC Cancer. 2014 Jul 9;14:495. doi: 10.1186/1471-2407-14-495.

11.

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.

Korbonits M, Jacobs RA, Aylwin SJ, Burrin JM, Dahia PL, Monson JP, Honegger J, Fahlbush R, Trainer PJ, Chew SL, Besser GM, Grossman AB.

J Clin Endocrinol Metab. 1998 Oct;83(10):3624-30.

PMID:
9768675
12.

A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells.

Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A.

J Clin Endocrinol Metab. 2003 Nov;88(11):5119-26.

PMID:
14602737
13.

Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma.

Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, Kreipe H, Lehmann U.

PLoS One. 2012;7(11):e49462. doi: 10.1371/journal.pone.0049462. Epub 2012 Nov 8.

14.

Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.

Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.

Endocr J. 2007 Jun;54(3):371-8. Epub 2007 Apr 10.

15.

Expression of FOXL2 in human normal pituitaries and pituitary adenomas.

Egashira N, Takekoshi S, Takei M, Teramoto A, Osamura RY.

Mod Pathol. 2011 Jun;24(6):765-73. doi: 10.1038/modpathol.2010.169. Epub 2011 Apr 8.

16.

Epimutations of the IG-DMR and the MEG3-DMR at the 14q32.2 imprinted region in two patients with Silver-Russell Syndrome-compatible phenotype.

Kagami M, Mizuno S, Matsubara K, Nakabayashi K, Sano S, Fuke T, Fukami M, Ogata T.

Eur J Hum Genet. 2015 Aug;23(8):1062-7. doi: 10.1038/ejhg.2014.234. Epub 2014 Nov 5.

17.

MEG3 noncoding RNA: a tumor suppressor.

Zhou Y, Zhang X, Klibanski A.

J Mol Endocrinol. 2012 Apr 2;48(3):R45-53. doi: 10.1530/JME-12-0008. Print 2012 Jun. Review.

18.

Coexpression of galanin and adrenocorticotropic hormone in human pituitary and pituitary adenomas.

Hsu DW, Hooi SC, Hedley-Whyte ET, Strauss RM, Kaplan LM.

Am J Pathol. 1991 Apr;138(4):897-909.

19.

Expression of neurotensin and its receptors in pituitary adenomas.

Giorgi RR, Chile T, Bello AR, Reyes R, Fortes MA, Machado MC, Cescato VA, Musolino NR, Bronstein MD, Giannella-Neto D, Corrêa-Giannella ML.

J Neuroendocrinol. 2008 Sep;20(9):1052-7. doi: 10.1111/j.1365-2826.2008.01761.x. Epub 2008 Jul 8.

PMID:
18624930
20.

The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.

Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M.

J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401. doi: 10.1210/jc.2007-2611. Epub 2008 Apr 1.

PMID:
18381572

Supplemental Content

Support Center